JM
Therapeutic Areas
Intellia Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NTLA-2002 (lonvoguran ziclumeran) | Hereditary Angioedema (HAE) | Phase 3 |
| NTLA-2001 | ATTR Amyloidosis (Cardiomyopathy/Polyneuropathy) | Phase 3 |
| NTLA-3001 | Hereditary Alpha-1 Antitrypsin Deficiency (AATD) | Phase 1/2 |
| NTLA-2003 | Glycogen Storage Disease Type Ia (GSDIa) | Preclinical |
Leadership Team at Intellia Therapeutics
LS
Laura Sepp-Lorenzino, Ph.D.
Executive Vice President, Chief Scientific Officer
DC
David C. Lubner
Executive Vice President, Chief Financial and Business Officer
JB
James B. Chung, M.D., Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
JD
Jennifer Doudna, Ph.D.
Co-Founder
AP
Andrew P. May, Ph.D.
Executive Vice President, Chief Corporate Strategy Officer